Doris Neuhauser is a seasoned clinical research and pharmaceutical professional with over 25 years of experience in leading the development and execution of clinical trials across various therapeutic areas and European markets. She has proven expertise in managing Phase I–III trials, with a strong focus on oncology, neuroscience, immunology, infectious diseases, inflammatory bowel disease (IBD), and rare diseases.

Doris spent 20 years at Eli Lilly, a global pharmaceutical company, where she focused on clinical research operations in the DACH region (Germany, Austria, Switzerland) and Italy. She also possesses extensive experience in global project management, with proficiency in applying Six Sigma methodologies.

She served as the Country Lead for Austria at TransCelerate, a global collaboration dedicated to innovating and streamlining drug development. Additionally, she was an active member of the Clinical Research Group of Pharmig, the Austrian Pharmaceutical Industry Association.

For the past six years, Doris has been serving as Country Head for Austria at PSI CRO, a global full-service contract research organization. In this role, she is responsible for full operational oversight, including resource allocation, budgeting, trial delivery, and regulatory compliance. She also acts as the primary liaison to executive leadership, regulatory authorities, and key stakeholders.

PSI Austria is an associate member of EUCROF (European CRO Federation), and Doris will co-host the EUCROF Annual Conference in February 2026 in Amsterdam.